Neuland Laboratories Ltd (NEULANDLAB) is currently trading at 19,570.60 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Neuland Laboratories is an India-headquartered pharmaceutical company focused on complex active pharmaceutical ingredients (APIs), contract development and manufacturing services (CDMO/CMS), generic differentiated solutions (GDS) and newer modalities such as peptides; the company operates multiple manufacturing units, exports to global markets, and has been investing in R&D, peptide manufacturing and sterile API capabilities to move up the value chain. Q1 FY27 performance showed a meaningful profit recovery: total income reported at INR650.1 crores, EBITDA of INR231.1 crores and an EBITDA margin of 35.5%, with PAT of INR147.4 crores. Working capital tightened materially — days reduced from 137 to 84 — while gross margin expanded to 61.2%, reflecting a favourable revenue mix and operating leverage during the quarter. Management is accelerating investments with commissioning of a commercial peptide block and multiple development projects already lined up; peptide Module 1 commissioning is imminent and the company reports projects ready to utilize that capacity even prior to full ramp, giving early validation to its multi-year peptide strategy. Neuland is deepening strategic positioning through a partnership with Gland Pharma to access aseptic sterile manufacturing and is actively expanding footprint via adjacent land acquisitions and long-term plans for additional manufacturing sites, signalling intent to scale both organically and through capability-focused alliances.

Over the past 52 weeks, Neuland Laboratories Ltd has traded between a low of ₹11,500.00 and a high of ₹24,235.05. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Neuland Laboratories Ltd has a market capitalization of approximately 24,730.83. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Neuland Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 49.68 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 24,730.83 Cr, Neuland Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Neuland Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Neuland Laboratories Ltd is 49.68. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The earnings conference call is scheduled for August 5, 2026 at 17:30 hours IST.

Revenue from operations in Q4FY26 was Rs 776.25 crore, compared with Rs 328.36 crore in Q4FY25, as per the disclosed results.

The 42nd AGM is scheduled for August 4, 2026 at 10:00 a.m. IST through Video Conferencing (VC) and Other Audio Visual Means (OAVM).

It is a ₹10,000 crore strategy aimed at making India a global biopharma manufacturing hub, focusing on biologics and biosimilars over the next five years.